BiotechTube

Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke, Cerebral Infarction

Trial Timeline

Mar 2, 2017 → Dec 13, 2019

NCT ID
NCT04486430

About Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos

Neu2000KWL + Neu2000KWL + Neu2000KWL + Placebos is a phase 2 stage product being developed by Sun Pharmaceutical for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT04486430. Target conditions include Stroke, Cerebral Infarction.

What happened to similar drugs?

13 of 20 similar drugs in Stroke were approved

Approved (13) Terminated (6) Active (4)
✅StatinShionogiApproved
✅AlteplaseKyowa KirinApproved
✅RepathaAmgenApproved
✅DonepezilPfizerApproved
✅Oral Anticoagulant + Antiplatelet DrugPfizerApproved
✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved
✅Clopidogrel + Clopidogrel placebo + AspirinBristol Myers SquibbApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04486430Phase 2Completed

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
36
Osmotic drugsSinopharmPre-clinical
33
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
SUN13837 + placeboDaiichi SankyoPhase 2
27
DS-1040b + AspirinDaiichi SankyoPhase 1
29
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
27
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
40
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
ASP2246Astellas PharmaPhase 1/2
39
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
AlteplaseKyowa KirinApproved
43
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
38
AbciximabEli LillyPhase 3
32
AbciximabEli LillyPhase 3
32
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
35